Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.88 |
| ▸ | CNR2 | P34972 | 1/20 | 0.77 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11174704 | 0.94 | PTGS2 (0.85) | PTGS2CNR2AKR1C3PTGS1HTR1A | |
| SCHEMBL15036529 | 0.92 | PTGS2 (0.75) | PTGS2CNR2AKR1C3PTGS1HTR1A | |
| SCHEMBL29170168 | 0.92 | PTGS2 (0.86) | PTGS2CNR2AKR1C3PTGS1HTR1A | |
| SCHEMBL16204760 | 0.91 | PTGS2 (0.73) | PTGS2CNR2AKR1C3PTGS1GLO1 | |
| SCHEMBL16010166 | 0.91 | PTGS2 (0.84) | PTGS2CNR2AKR1C3PTGS1HTR1A | |
| SCHEMBL11251708 | 0.91 | PTGS2 (0.85) | PTGS2CNR2AKR1C3PTGS1HTR1A | |
| SCHEMBL13813542 | 0.90 | PTGS2 (1.00) | PTGS2CNR2AKR1C3PTGS1HTR1A | |
| SCHEMBL12742120 | 0.90 | PTGS2 (0.91) | PTGS2CNR2AKR1C3PTGS1HTR1A | |
| SCHEMBL30077218 | 0.90 | PTGS2 (0.91) | PTGS2CNR2AKR1C3PTGS1HTR1A | |
| SCHEMBL19376389 | 0.90 | PTGS2 (0.84) | PTGS2CNR2AKR1C3PTGS1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710086-B1 | CHEMICALLY MODIFIED PHARMACOLOGICALLY ACTIVE AGENT IN CARRIER; REDUCE THE DAMAGE TO THE GASTROINTESTINAL TRACT | MEDINOX, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20030087840-A1 | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor | MEDINOX, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6407135-B1 | NITRIC OXIDE SCAVENGER COVALENTLY BONDED TO NON-STEROIDAL ANTIINFLAMMATORY AGENT OR OTHER DRUG; SIDE EFFECT REDUCTION | MEDINOX, INC. | 2002-06-18 | — | — | US | disclosed |
| US-6274627-B1 | ADMINISTERING COMPOUNDS SUCH AS N-METHYL-D-GLUCAMINE DITHIO-CARBAMATE DISULFIDE FOR IN VIVO REDUCTION OF FREE RADICAL LEVELS IN A SUBJECT | MEDINOX, INC. | 2001-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087840-A1 | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor | NOS1, PTGS1, NOS2 | PTGS2 14/4885CNR2 1137/4885AKR1C3 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.